On December 24, 2025, the Delhi High Court delivered a ruling that, while technical on its face, carries deep strategic consequences for India’s pharmaceutical ecosystem. In Zydus Healthcare Ltd. v. Assistant Controller of Patents & Anr., the court refused to upset the grant of a patent to Swiss drugmaker Helsinn for a nausea medication — and in doing so, clarified how India’s patent system is meant to operate in practice.
The Case in a Nutshell
Free Membership Required
You must be a Free member to access this content.
Already a member? Log in here
